Topical Vehicle Selection: Myths and Reality

During the development of a dermal drug, much efforts tend to be placed on improving its delivery through skin. These efforts are driven by the known risk of not engaging the target. Indeed to increase comfort that the target will be engaged one need to try fullfill as best as it can evidence of (1) sufficient compound on board for a desired time (i.e., PK within skin) and (2) demonstration of pharmacological activity [1].

[1]  R. Damstra,et al.  Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study , 2003, BMJ : British Medical Journal.

[2]  S. Kazarian,et al.  Membrane transport of hydrocortisone acetate from supersaturated solutions; the role of polymers. , 2001, International journal of pharmaceutics.

[3]  D. Piwnica,et al.  Vasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidine. , 2014, Journal of dermatological science.

[4]  J. Hadgraft,et al.  Effect of finite doses of propylene glycol on enhancement of in vitro percutaneous permeation of loperamide hydrochloride. , 2004, International journal of pharmaceutics.

[5]  J Hadgraft,et al.  Crystallization of hydrocortisone acetate: influence of polymers. , 2001, International journal of pharmaceutics.

[6]  Paul Morgan,et al.  Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. , 2012, Drug discovery today.

[7]  S. Mariz,et al.  The development and registration of topical pharmaceuticals. , 2012, International journal of pharmaceutics.

[8]  S. Mitragotri.  Devices for overcoming biological barriers: the use of physical forces to disrupt the barriers. , 2013, Advanced drug delivery reviews.

[9]  C. Main,et al.  Patients with psoriasis and their compliance with medication. , 1999, Journal of the American Academy of Dermatology.

[10]  S. Feldman,et al.  Topical Clobetasol Propionate in the Treatment of Psoriasis , 2009, American journal of clinical dermatology.

[11]  S. Feldman,et al.  Clobetasol propionate for psoriasis: are ointments really more potent? , 2006, Journal of drugs in dermatology : JDD.

[12]  I. Alberti,et al.  Non-invasive assessment of the effect of formulation excipients on stratum corneum barrier function in vivo. , 2004, International journal of pharmaceutics.

[13]  B. Diffey,et al.  In vitro assessment of the broad-spectrum ultraviolet protection of sunscreen products. , 2000, Journal of the American Academy of Dermatology.

[14]  Russell O. Potts,et al.  Predicting Skin Permeability , 1992, Pharmaceutical Research.

[15]  P. Wiedeman,et al.  Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases. , 1998, Current pharmaceutical design.

[16]  R. Horne.  Adherence to Treatment , 2018, Handbook of Health Psychology.

[17]  K. Arakane,et al.  Relationship between sun‐protection factor and application thickness in high‐performance sunscreen: double application of sunscreen is recommended , 2012, Clinical and experimental dermatology.

[18]  P. Dugard,et al.  A comparison of the in vitro permeability properties of human and some laboratory animal skins , 1986, International journal of cosmetic science.